Secondary Market for Late-Stage Rare Disease Therapies | Craig Martin, David Barrett, Nicole Grubner скачать в хорошем качестве

Secondary Market for Late-Stage Rare Disease Therapies | Craig Martin, David Barrett, Nicole Grubner

Craig Martin, CEO of Orphan Therapeutics Accelerator, and David Barrett, CEO of the American Society of Gene and Cell Therapy, join host Nicole Grubner of FINN Partners for a direct conversation about a growing biotech reality. Late stage rare disease therapies can stall even when the science is strong. The limiting factor is often the development model rather than the clinical promise. This session of the Global BioInnovation Forum, presented by FINN Partners in partnership with 1BusinessWorld during the J.P. Morgan Healthcare Conference, explores a newly announced collaboration to create a clearinghouse style marketplace for late stage cell and gene therapy assets. The goal is to help programs that have been shelved or deprioritized find a practical path forward through new types of sponsors, partners, and capital. The discussion covers why assets get stranded, what a secondary market can unlock, and which partners are best positioned to carry programs to patients, including academic medical centers, patient advocacy groups, mission aligned investors, and specialized operators. The session also explains how AI can support diligence at scale, increase transparency, and improve matchmaking while keeping expert oversight central. The conversation closes with the human impact, including why continuity matters for active trials, why delays hit pediatric and ultra rare communities hardest, and why preserving momentum can protect both patients and the integrity of clinical data. If you work in rare disease, cell and gene therapy, biotech investing, patient advocacy, clinical development, or healthcare innovation, this is a practical view of what could become a new lane for late stage programs that still deserve to reach patients. 00:00:20 Session opening and why late stage therapies stall 00:01:44 Craig Martin and the Orphan Therapeutics Accelerator model 00:09:08 David Barrett and the ASGCT perspective on system barriers 00:18:24 Who the clearinghouse aims to attract and why it matters 00:26:14 How AI supports diligence and scaling decisions 00:30:05 Human impact and why trial continuity matters 00:34:03 Closing #RareDisease #GeneTherapy #CellTherapy #Biotech #HealthInnovation